Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

Based in San Diego, California, ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to outperform in 2025. Here’s what you need to know.

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered ...

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. OUT, ...

Read more. ResMed CPAP masks subject to Class I recall over magnetic interference issue Six reported injuries related to magnets on the headgear of CPAP machines by ResMed Ltd. have resulted in a ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Thanks to the growing awareness of sleep disorders, such as sleep apnoea, and its industry-leading masks and software solutions, ResMed has consistently reported strong sales and earnings growth ...